NO20054411L - Terapeutiske midler omfattende et anti-angiogent middel i kombinasjon med en SRC-inhibitor og deres terapeutiske anvendelse - Google Patents

Terapeutiske midler omfattende et anti-angiogent middel i kombinasjon med en SRC-inhibitor og deres terapeutiske anvendelse

Info

Publication number: NO20054411L
Authority: NO; Norway
Prior art keywords: combination; angiogenic agent; therapeutic; src inhibitor; therapeutic agents
Prior art date: 2003-05-07

Application number

NO20054411A

Other languages

English (en)

Norwegian (no)

Other versions

NO20054411D0 (no

Inventor

Jon Owen Curwen

Stephen Robert Wedge

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-05-07

Filing date

2005-09-23

Publication date

2005-11-30

2005-09-23 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2005-09-23 Publication of NO20054411D0 publication Critical patent/NO20054411D0/no

2005-11-30 Publication of NO20054411L publication Critical patent/NO20054411L/no

Links

239000004037 angiogenesis inhibitor Substances 0.000 title abstract 3
239000003814 drug Substances 0.000 title abstract 2
229940122924 Src inhibitor Drugs 0.000 title 1
229940124597 therapeutic agent Drugs 0.000 title 1
230000001225 therapeutic effect Effects 0.000 title 1
206010020772 Hypertension Diseases 0.000 abstract 1
241000124008 Mammalia Species 0.000 abstract 1
230000033115 angiogenesis Effects 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
229940043355 kinase inhibitor Drugs 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
102000037979 non-receptor tyrosine kinases Human genes 0.000 abstract 1
108091008046 non-receptor tyrosine kinases Proteins 0.000 abstract 1
239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO20054411A 2003-05-07 2005-09-23 Terapeutiske midler omfattende et anti-angiogent middel i kombinasjon med en SRC-inhibitor og deres terapeutiske anvendelse NO20054411L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0310401.5A GB0310401D0 (en)	2003-05-07	2003-05-07	Therapeutic agent
PCT/GB2004/001939 WO2004098604A1 (en)	2003-05-07	2004-05-04	Therapeutic agents comprising an anti-angiogenic agent in combination with an src-inhibitor and their therapeutic use

Publications (2)

Publication Number	Publication Date
NO20054411D0 NO20054411D0 (no)	2005-09-23
NO20054411L true NO20054411L (no)	2005-11-30

Family

ID=9957542

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20054411A NO20054411L (no)	2003-05-07	2005-09-23	Terapeutiske midler omfattende et anti-angiogent middel i kombinasjon med en SRC-inhibitor og deres terapeutiske anvendelse

Country Status (14)

Country	Link
US (2)	US20060223815A1 (pt)
EP (1)	EP1620104A1 (pt)
JP (1)	JP2006525304A (pt)
KR (1)	KR20060009893A (pt)
CN (1)	CN100418531C (pt)
AU (1)	AU2004237132B2 (pt)
BR (1)	BRPI0409742A (pt)
CA (1)	CA2519930A1 (pt)
GB (1)	GB0310401D0 (pt)
MX (1)	MXPA05011858A (pt)
NO (1)	NO20054411L (pt)
NZ (1)	NZ542348A (pt)
WO (1)	WO2004098604A1 (pt)
ZA (1)	ZA200508858B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0008269D0 (en)	2000-04-05	2000-05-24	Astrazeneca Ab	Combination chemotherapy
US7462623B2 (en) *	2002-11-04	2008-12-09	Astrazeneca Ab	Quinazoline derivatives as Src tyrosine kinase inhibitors
GB0226434D0 (en) *	2002-11-13	2002-12-18	Astrazeneca Ab	Combination product
CA2553433A1 (en)	2004-01-23	2005-08-11	Amgen Inc.	Quinoline quinazoline pyridine and pyrimidine compounds and their use in the treatment of inflammation angiogenesis and cancer
JP4932495B2 (ja)	2004-01-23	2012-05-16	アムゲンインコーポレイテッド	化合物及び使用方法
GB0406446D0 (en) *	2004-03-23	2004-04-28	Astrazeneca Ab	Combination therapy
GB0406445D0 (en) *	2004-03-23	2004-04-28	Astrazeneca Ab	Combination therapy
US20080113039A1 (en) *	2004-03-23	2008-05-15	Stephen Robert Wedge	Combination Therapy
GB0412074D0 (en)	2004-05-29	2004-06-30	Astrazeneca Ab	Combination product
US7652009B2 (en)	2004-11-30	2010-01-26	Amgem Inc.	Substituted heterocycles and methods of use
GB0427697D0 (en) *	2004-12-17	2005-01-19	Astrazeneca Ab	Chemical process
JO2787B1 (en)	2005-04-27	2014-03-15	امجين إنك,	Alternative amide derivatives and methods of use
WO2007003933A2 (en) *	2005-07-06	2007-01-11	Astrazeneca Ab	Combination therapy of cancer with azd2171 and gemcitabine
CA2620436A1 (en) *	2005-08-26	2007-03-01	Antisoma Plc	Combinations comprising dmxaa for the treatment of cancer
CA2631676A1 (en) *	2005-12-22	2007-06-28	Astrazeneca Ab	Combination of azd2171 and pemetrexed
EP2220078B1 (en) *	2007-10-29	2013-05-22	Amgen, Inc	Benzomorpholine derivatives and methods of use
WO2009068906A2 (en) *	2007-11-26	2009-06-04	Astrazeneca Ab	Combinations comprising zd4054 and a src family kinase inhibitor 172
US9688688B2 (en)	2013-02-20	2017-06-27	Kala Pharmaceuticals, Inc.	Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
CA2928665A1 (en) *	2013-11-01	2015-05-07	Kala Pharmaceuticals, Inc.	Crystalline forms of therapeutic compounds and uses thereof
US9890173B2 (en)	2013-11-01	2018-02-13	Kala Pharmaceuticals, Inc.	Crystalline forms of therapeutic compounds and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9508538D0 (en) *	1995-04-27	1995-06-14	Zeneca Ltd	Quinazoline derivatives
BRPI0017548B8 (pt) *	1999-02-10	2023-05-02	Astrazeneca Ab	Composto
GB0008269D0 (en) *	2000-04-05	2000-05-24	Astrazeneca Ab	Combination chemotherapy
UA73993C2 (uk) *	2000-06-06	2005-10-17	Астразенека Аб	Хіназолінові похідні для лікування пухлин та фармацевтична композиція
US7115615B2 (en) *	2000-08-21	2006-10-03	Astrazeneca	Quinazoline derivatives
WO2002092579A1 (en) *	2001-05-14	2002-11-21	Astrazeneca Ab	4-anilinoquinazoline derivatives
GB0126879D0 (en) *	2001-11-08	2002-01-02	Astrazeneca Ab	Combination therapy
GB0218526D0 (en) *	2002-08-09	2002-09-18	Astrazeneca Ab	Combination therapy
US20050222183A1 (en) *	2002-08-09	2005-10-06	Wedge Stephen R	Combination of zd6474, an inhibitor of the vascular endothelial growth factor receptor, with radiotherapy in the treatment of cancer
GB0223380D0 (en) *	2002-10-09	2002-11-13	Astrazeneca Ab	Combination therapy
GB0226434D0 (en) *	2002-11-13	2002-12-18	Astrazeneca Ab	Combination product
DK1592423T3 (da) *	2003-02-13	2011-06-27	Astrazeneca Ab	Kombinationsterapi af ZD6474 med 5-FU og/eller CPT-11
GB0316123D0 (en) *	2003-07-10	2003-08-13	Astrazeneca Ab	Combination therapy
US20060167027A1 (en) *	2003-07-10	2006-07-27	Wedge Stephen R	Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
GB0316127D0 (en) *	2003-07-10	2003-08-13	Astrazeneca Ab	Combination therapy
US20080113039A1 (en) *	2004-03-23	2008-05-15	Stephen Robert Wedge	Combination Therapy
GB0406445D0 (en) *	2004-03-23	2004-04-28	Astrazeneca Ab	Combination therapy
GB0412074D0 (en) *	2004-05-29	2004-06-30	Astrazeneca Ab	Combination product
KR20070073813A (ko) *	2004-09-27	2007-07-10	아스트라제네카 아베	Ａｚｄ2171 및 이마티닙을 포함하는 암의 병합 요법
MX2007003505A (es) *	2004-09-27	2007-05-10	Astrazeneca Ab	Combinacion que comprende zd6474 e imatinib.
GB0424339D0 (en) *	2004-11-03	2004-12-08	Astrazeneca Ab	Combination therapy
JP4834985B2 (ja) *	2004-12-10	2011-12-14	日産自動車株式会社	組電池の容量調整装置

2003
- 2003-05-07 GB GBGB0310401.5A patent/GB0310401D0/en not_active Ceased
2004
- 2004-05-04 JP JP2006506222A patent/JP2006525304A/ja active Pending
- 2004-05-04 CA CA002519930A patent/CA2519930A1/en not_active Abandoned
- 2004-05-04 WO PCT/GB2004/001939 patent/WO2004098604A1/en not_active Ceased
- 2004-05-04 AU AU2004237132A patent/AU2004237132B2/en not_active Ceased
- 2004-05-04 EP EP04731049A patent/EP1620104A1/en not_active Withdrawn
- 2004-05-04 MX MXPA05011858A patent/MXPA05011858A/es unknown
- 2004-05-04 US US10/555,389 patent/US20060223815A1/en not_active Abandoned
- 2004-05-04 NZ NZ542348A patent/NZ542348A/en unknown
- 2004-05-04 KR KR1020057020997A patent/KR20060009893A/ko not_active Ceased
- 2004-05-04 BR BRPI0409742-4A patent/BRPI0409742A/pt not_active IP Right Cessation
- 2004-05-04 CN CNB2004800120898A patent/CN100418531C/zh not_active Expired - Fee Related
2005
- 2005-09-23 NO NO20054411A patent/NO20054411L/no not_active Application Discontinuation
- 2005-11-01 ZA ZA200508858A patent/ZA200508858B/en unknown
2009
- 2009-09-28 US US12/568,643 patent/US20100029673A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CN1784232A (zh)	2006-06-07
US20060223815A1 (en)	2006-10-05
CA2519930A1 (en)	2004-11-18
GB0310401D0 (en)	2003-06-11
CN100418531C (zh)	2008-09-17
WO2004098604A1 (en)	2004-11-18
AU2004237132A1 (en)	2004-11-18
MXPA05011858A (es)	2006-02-17
AU2004237132B2 (en)	2007-10-18
NO20054411D0 (no)	2005-09-23
KR20060009893A (ko)	2006-02-01
JP2006525304A (ja)	2006-11-09
ZA200508858B (en)	2007-03-28
NZ542348A (en)	2009-01-31
US20100029673A1 (en)	2010-02-04
EP1620104A1 (en)	2006-02-01
BRPI0409742A (pt)	2006-05-09

Legal Events

Date	Code	Title	Description
2010-12-27	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
MXPA05011858A (es)	2006-02-17	Agentes terapeuticos que comprenden un agente antiagiongenico en combinacion con un inhibidor src y su uso terapeutico.
DE60332433D1 (de)	2010-06-17	Azolylaminoazine als proteinkinasehemmer
NO20074446L (no)	2007-11-01	DR5-antistoffer og anvendelser derav
DE60314603D1 (de)	2007-08-09	Zusammensetzungen brauchbar als protein-kinase- inhibitoren
ATE468336T1 (de)	2010-06-15	Azolylaminoazine als proteinkinasehemmer
NO20074431L (no)	2007-08-31	Pyrrolopyrimidiner nyttige som proteinkinaseinhibitorer
UY28958A1 (es)	2005-08-31	Nuevos derivados de piridazin-3(2h)-ona
NO20064976L (no)	2006-10-31	Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser
NO20052595L (no)	2005-06-27	Sammensetninger anvendelige som inhibitorer av ROCK- og andre proteinkinaser.
MY139689A (en)	2009-10-30	Imidazotriazines as protein kinase inhibitors
NO20073140L (no)	2007-06-20	Pyrrolopyraziner og pyralopyraziner som er nyttige som inhibitorer av proteinkinaser
NO20082508L (no)	2008-07-31	Aminopyrimidiner anvendelige som kinaseinhibitorer
NO20092130L (no)	2009-06-17	Tricykliske heteroarylforbindelser anvendelige som inhibitorer of januskinase
DE602005020611D1 (de)	2010-05-27	Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen
NO20082026L (no)	2008-06-25	Deazapuriner som er nyttige som inhibitorer for Janus-kinaser
NO20061323L (no)	2006-06-09	Kinazolinderivater
DE60327999D1 (de)	2009-07-30	Azolylaminoazine als inhibitoren von proteinkinasen
NO20064895L (no)	2006-12-19	6,6-Bisykliske ring-substituerte heterobisykliske protein-kinase inhibitorer
NO20080675L (no)	2008-03-13	P38-Map kinaseinhibitorer og metoder for deres anvendelse
NO20070514L (no)	2007-03-12	Pyrrolotriazin kinase inhibitorer
NO20061743L (no)	2006-06-21	Kinazolinderivater
TN2009000444A1 (en)	2011-03-31	Combination therapy with a compound acting as a plateletadp receptor inhibitor
UY28931A1 (es)	2005-12-30	Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
NO20061322L (no)	2006-06-15	Kinazolinderivater som tyrosin kinase inhibitorer
NO20060328L (no)	2006-02-17	Kombinasjon av mGluR2-antagonist og ACHE-inhibitor for behandiing av akutt og/eller kronisk neurologiske forstyrrelser